DeepMed Research

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

High-Resolution PET-CT Imaging for Surgical Margin Visualization

Not Applicable

Not yet recruiting

Conditions: Cancer
Solid Malignant Tumors

First Posted Date: 2025-04-08

Last Posted Date: 2025-04-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 50

Registration Number: NCT06915454

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment with HER2-targeted Therapy

Early Phase 1

Not yet recruiting

Conditions: Locally Advanced Cancer
Metastatic Cancer

Interventions: Drug: ABY-025 Loading Dose
Drug: [68Ga]Ga-ABY-025

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-30

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT06828588

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

Early Phase 1

Recruiting

Conditions: HNSCC
HNSCC,Larynx, Pharynx and Oral Cavity

Interventions: Drug: Panitumumab IRDye 800

First Posted Date: 2025-02-11

Last Posted Date: 2025-05-13

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 18

Registration Number: NCT06819228

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository

Recruiting

Conditions: Clonal Hematopoiesis

First Posted Date: 2024-11-22

Last Posted Date: 2024-11-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 800

Registration Number: NCT06701214

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules

Not Applicable

Recruiting

Conditions: Lung Neoplasm

First Posted Date: 2024-10-15

Last Posted Date: 2024-11-07

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 400

Registration Number: NCT06638398

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial

Not Applicable

Recruiting

Conditions: Stage I Lung Cancer
Stage II Lung Cancer

Interventions: Procedure: Cryosurgery
Procedure: Robotic Bronchoscopy
Procedure: Bronchoscopy with Biopsy
Procedure: Resection
Procedure: Chest Radiography
Procedure: Computed Tomography
Procedure: Biospecimen Collection
Other: Electronic Health Record Review

First Posted Date: 2024-09-19

Last Posted Date: 2024-11-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT06593106

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan

Recruiting

Conditions: Sarcoma

Interventions: Other: Surveys
Other: Blood Collection
Other: Saliva Collection
Other: Urine Collection
Other: Stool Collection
Other: Tissue collection
Other: Physical Activity Monitoring

First Posted Date: 2024-07-01

Last Posted Date: 2024-07-01

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 2100

Registration Number: NCT06482957

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Relapsed Myelodysplastic Syndrome
Refractory Myelodysplastic Syndrome
Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Eltanexor
Drug: Venetoclax
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Biospecimen Collection

First Posted Date: 2024-05-06

Last Posted Date: 2025-03-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 60

Registration Number: NCT06399640

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Stage I Lung Cancer
Stage II Lung Cancer
Limited Stage Lung Small Cell Carcinoma
Stage III Lung Cancer

Interventions: Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide
Biological: Pembrolizumab
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Biospecimen Collection
Radiation: Radiation Therapy

First Posted Date: 2023-11-20

Last Posted Date: 2024-05-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 20

Registration Number: NCT06140407

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

Phase 1

Recruiting

Conditions: Stage IV Lung Cancer
Extensive Stage Lung Small Cell Carcinoma

Interventions: Drug: Carboplatin
Biological: Atezolizumab
Drug: Etoposide
Radiation: Total Body Irradiation
Radiation: Hypofractionated Radiation Therapy
Procedure: Magnetic Resonance Imaging

First Posted Date: 2023-10-31

Last Posted Date: 2024-06-20

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 18

Registration Number: NCT06110572

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy